Lyndsey Runaas, MD
Hematology & Oncology · Madison, WINPI 1265758668
Payments from drug & device makers
Across 29 payments — averaging $1172.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$21K
- Servier Pharmaceuticals LLC$6K
- Agios Pharmaceuticals, Inc.$3K
- Blueprint Medicines Corporation$3K
- National Marrow Donor Program$1K
- Beigene USA, Inc.$258
- plus $457 from 5 others
What the payments were for
- Consulting fees$4,76040%
- Speaking & faculty fees$5,14943%
- Travel & lodging$1,21610%
- Food & beverage$9248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 2 | $20,764 |
| Servier Pharmaceuticals LLC | 8 | $5,826 |
| Agios Pharmaceuticals, Inc. | 9 | $2,910 |
| Blueprint Medicines Corporation | 1 | $2,599 |
| National Marrow Donor Program | 2 | $1,177 |
| Beigene USA, Inc. | 2 | $258 |
| AstraZeneca | 1 | $150 |
| Jazz Pharmaceuticals Inc. | 1 | $124 |
| Tempus AI, Inc | 1 | $115 |
| Bristol Myers Squibb | 1 | $50 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,990 in reported general payments places this provider in the 65th percentile of 248 hematology & oncology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RezurockBelumosudil Mesylate | 15 | $525,852 |
| JakafiRuxolitinib Phosphate | 14 | $83,542 |
| BexseroMeningococcal B Vaccine,4-Comp | 13 | $3,039 |
| Menveo A-C-Y-W-135-DipMening Vac A,c,y,w-135 Dip/Pf | 13 | $2,369 |
| Acyclovir | 56 | $2,321 |
| Ursodiol | 12 | $964 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Madison
- Christos KyriakopoulosMadison$17.1M
- Ryan PorterMadison$6.1M
- Vaishalee KenkreMadison$3.9M
- Hamid EmamekhooMadison$2.6M
- Jeremy KratzMadison$1.6M
- Timothy SchmidtMadison$1.2M
- Vincent MaMadison$1.2M
- Saurabh RajguruMadison$944K
- Sam LubnerMadison$851K
- Elisavet PaplomataMadison$521K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.